Verastem Reports Q1 Revenue of $18.67M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Reports Q1 revenue $18.67M, consensus $21.39M. "As we mark the one-year anniversary of the FDA-approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, I am incredibly proud of the progress we have made to deliver a meaningful impact for people living with this rare cancer," said Dan Paterson, president and chief executive officer at Verastem Oncology. "As we build on the foundation we have established with the commercial launch, we also look to continue accelerating VS-7375, our potential best-in-class oral, KRAS G12D (ON/OFF) inhibitor, and are pleased to announce the initiation of three Phase 2 registration-directed trials in pancreatic, non-small cell lung, and colorectal cancers. In an evolving competitive landscape, we remain encouraged by the efficacy data generated by our partner and emerging in the U.S., along with the safety and tolerability profile we are seeing across multiple solid tumor cancers and look forward to sharing data updates throughout this year. Altogether, we believe we are well-positioned to drive strong execution across our commercial launch and expedite VS-7375 development while maintaining disciplined capital management."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VSTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VSTM
Wall Street analysts forecast VSTM stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.130
Low
14.00
Averages
15.60
High
20.00
Current: 4.130
Low
14.00
Averages
15.60
High
20.00
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Verastem Oncology Announces Investor Conference Schedule
- Investor Conference Schedule: Verastem Oncology is set to participate in the HCW 4th Annual BioConnect Investor Conference on May 19, 2026, and the RBC Global Healthcare Conference on May 20, 2026, showcasing advancements in RAS/MAPK pathway-driven cancers, which is expected to attract investor interest and enhance company visibility.
- Webcast Availability: The company will provide live webcasts of the presentations on its website under the 'Events & Presentations' section, with replays available for approximately 90 days post-event, ensuring that investors unable to attend live can still access critical information.
- Product Market Positioning: Verastem Oncology focuses on developing and commercializing new medicines, particularly for patients with RAS/MAPK pathway-driven cancers, with existing products like AVMAPKI® and FAKZYNJA® CO-PACK in the market, indicating the company's potential in the biopharmaceutical sector.
- R&D Pipeline Focus: The company's pipeline emphasizes novel small molecule drugs that inhibit critical signaling pathways promoting cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition, showcasing its innovative capabilities in cancer treatment.
See More
Launch of LGSOC Resource Guide to Support Patients
- Resource Integration: The STAAR Low-Grade Serous Ovarian Cancer Foundation and Verastem Oncology have launched the LGSOC Resource Guide, designed to provide comprehensive educational materials and community resources for patients and caregivers dealing with this rare form of ovarian cancer, thereby addressing significant informational gaps.
- Patient Engagement: The guide's release coincides with World Ovarian Cancer Day, emphasizing the critical role of patients in treatment decision-making, which helps them transition from feeling powerless to becoming active participants in their care, ultimately enhancing their quality of life and treatment confidence.
- FDA Interaction: In 2023, STAAR held its first-ever Externally-led Patient-Focused Drug Development meeting with the FDA, advancing recognition of LGSOC as a distinct disease requiring dedicated treatment approaches, which facilitated the development of the first FDA-approved treatment for KRAS-mutated recurrent LGSOC.
- Mental Health Focus: LGSOC patients face significant mental and physical health challenges, and the resource guide offers support information regarding emotional well-being and fertility, aiming to assist patients and their families in obtaining necessary support and information when confronting the disease.
See More
Verastem Q1 2026 Earnings Call Insights
- Revenue Growth: Verastem achieved $18.7 million in net product revenue for Q1 2026, reflecting steady quarter-over-quarter growth and bringing total net revenue close to $50 million, indicating a stable market presence and potential for future expansion.
- Leadership Change: The appointment of Dan Lyons as the new Chief Commercial Officer aims to enhance commercial execution, expected to drive effective transformations in marketing and sales strategies, thereby improving overall performance.
- R&D Expenses: The company reported $38.2 million in R&D expenses for Q1, and despite facing seasonal challenges, it remains on track to achieve self-sustainability for the LGSOC franchise in the second half of 2026, demonstrating confidence in future profitability.
- Clinical Advancements: Verastem anticipates initiating three registration-directed Phase II clinical trials for pancreatic cancer, non-small cell lung cancer, and colorectal cancer by mid-2026, further unlocking the market potential of VS-7375 and boosting investor confidence.
See More
Verastem Q1 2026 Earnings Beat Expectations
- Earnings Highlights: Verastem's Q1 non-GAAP EPS of -$0.43 beats expectations by $0.04, although revenue of $18.67M misses by $2.72M, indicating improvements in cost management despite revenue challenges.
- Clinical Trial Progress: Early data from the TARGET-D 101 trial is expected to be reported in 1H 2026, with an update on the trial's progress in 2H 2026, reflecting the company's ongoing commitment to R&D.
- New Trial Initiation: The first patient in the TARGET-D 201, TARGET-D 202, and TARGET-D 203 clinical trials is expected to be initiated in mid-2026, showcasing the company's proactive approach in drug development.
- Future Milestones: The RAMP 205 trial is set to report updates on safety and efficacy of the expansion cohort in Q2 2026, which is anticipated to provide critical data for metastatic pancreatic cancer treatment, further advancing the company's strategic development in oncology.
See More
Verastem Launches New Treatment for LGSOC
- FDA Approval: Verastem Oncology's AVMAPKI®FAKZYNJA®CO-PACK received accelerated FDA approval on May 8, 2025, specifically designed for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have undergone prior systemic therapy, marking a significant advancement in treatment options.
- Patient Support Initiative: The newly launched 'Reimagine Recurrent LGSOC' campaign aims to provide emotional resonance and practical information for both patients and healthcare professionals, helping patients better manage their condition and set treatment expectations, thereby enhancing their quality of life.
- Market Demand Response: LGSOC is a rare cancer with a high recurrence rate, with approximately 30% of patients harboring KRAS mutations; Verastem's treatment not only fills a critical gap in this therapeutic area but also offers renewed hope for patients, potentially driving the company's growth in the biopharmaceutical market.
- Clinical Trial Plans: Verastem is conducting the international Phase 3 confirmatory trial RAMP 301 to evaluate the combination of AVMAPKI and FAKZYNJA against standard chemotherapy, further validating its clinical benefits to ensure continued FDA approval.
See More
RAMP 201 Clinical Trial Data Released
- Sustained Efficacy: In the RAMP 201 clinical trial, after a median follow-up of two years, 52% of patients with KRAS mutations and 30% of KRAS wild-type patients remained on therapy for over one year, indicating the durability and effectiveness of the treatment, potentially offering long-term options for patients.
- Good Safety Profile: The combination therapy demonstrated no new safety signals during the two-year follow-up, with only a 12% discontinuation rate due to adverse events, suggesting that the treatment regimen is well-tolerated over extended periods, thereby enhancing patient confidence in the therapy.
- Optimal Efficacy Analysis: Recent exposure-response analysis indicates that the best therapeutic effect of the combination therapy with avutometinib and defactinib is achieved at the approved doses, emphasizing the importance of dosing and scheduling, which provides guidance for clinical practice.
- Clinical Significance: The findings reveal that approximately one-third of patients without KRAS mutations continued treatment after one year, highlighting the importance of this combination therapy in a patient population with limited treatment options, potentially paving the way for new therapeutic strategies in the future.
See More
Verastem Oncology Announces Investor Conference Schedule
- Investor Conference Schedule: Verastem Oncology is set to participate in the HCW 4th Annual BioConnect Investor Conference on May 19, 2026, and the RBC Global Healthcare Conference on May 20, 2026, showcasing advancements in RAS/MAPK pathway-driven cancers, which is expected to attract investor interest and enhance company visibility.
- Webcast Availability: The company will provide live webcasts of the presentations on its website under the 'Events & Presentations' section, with replays available for approximately 90 days post-event, ensuring that investors unable to attend live can still access critical information.
- Product Market Positioning: Verastem Oncology focuses on developing and commercializing new medicines, particularly for patients with RAS/MAPK pathway-driven cancers, with existing products like AVMAPKI® and FAKZYNJA® CO-PACK in the market, indicating the company's potential in the biopharmaceutical sector.
- R&D Pipeline Focus: The company's pipeline emphasizes novel small molecule drugs that inhibit critical signaling pathways promoting cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition, showcasing its innovative capabilities in cancer treatment.
See More
Launch of LGSOC Resource Guide to Support Patients
- Resource Integration: The STAAR Low-Grade Serous Ovarian Cancer Foundation and Verastem Oncology have launched the LGSOC Resource Guide, designed to provide comprehensive educational materials and community resources for patients and caregivers dealing with this rare form of ovarian cancer, thereby addressing significant informational gaps.
- Patient Engagement: The guide's release coincides with World Ovarian Cancer Day, emphasizing the critical role of patients in treatment decision-making, which helps them transition from feeling powerless to becoming active participants in their care, ultimately enhancing their quality of life and treatment confidence.
- FDA Interaction: In 2023, STAAR held its first-ever Externally-led Patient-Focused Drug Development meeting with the FDA, advancing recognition of LGSOC as a distinct disease requiring dedicated treatment approaches, which facilitated the development of the first FDA-approved treatment for KRAS-mutated recurrent LGSOC.
- Mental Health Focus: LGSOC patients face significant mental and physical health challenges, and the resource guide offers support information regarding emotional well-being and fertility, aiming to assist patients and their families in obtaining necessary support and information when confronting the disease.
See More
Verastem Q1 2026 Earnings Call Insights
- Revenue Growth: Verastem achieved $18.7 million in net product revenue for Q1 2026, reflecting steady quarter-over-quarter growth and bringing total net revenue close to $50 million, indicating a stable market presence and potential for future expansion.
- Leadership Change: The appointment of Dan Lyons as the new Chief Commercial Officer aims to enhance commercial execution, expected to drive effective transformations in marketing and sales strategies, thereby improving overall performance.
- R&D Expenses: The company reported $38.2 million in R&D expenses for Q1, and despite facing seasonal challenges, it remains on track to achieve self-sustainability for the LGSOC franchise in the second half of 2026, demonstrating confidence in future profitability.
- Clinical Advancements: Verastem anticipates initiating three registration-directed Phase II clinical trials for pancreatic cancer, non-small cell lung cancer, and colorectal cancer by mid-2026, further unlocking the market potential of VS-7375 and boosting investor confidence.
See More
Verastem Q1 2026 Earnings Beat Expectations
- Earnings Highlights: Verastem's Q1 non-GAAP EPS of -$0.43 beats expectations by $0.04, although revenue of $18.67M misses by $2.72M, indicating improvements in cost management despite revenue challenges.
- Clinical Trial Progress: Early data from the TARGET-D 101 trial is expected to be reported in 1H 2026, with an update on the trial's progress in 2H 2026, reflecting the company's ongoing commitment to R&D.
- New Trial Initiation: The first patient in the TARGET-D 201, TARGET-D 202, and TARGET-D 203 clinical trials is expected to be initiated in mid-2026, showcasing the company's proactive approach in drug development.
- Future Milestones: The RAMP 205 trial is set to report updates on safety and efficacy of the expansion cohort in Q2 2026, which is anticipated to provide critical data for metastatic pancreatic cancer treatment, further advancing the company's strategic development in oncology.
See More
Verastem Launches New Treatment for LGSOC
- FDA Approval: Verastem Oncology's AVMAPKI®FAKZYNJA®CO-PACK received accelerated FDA approval on May 8, 2025, specifically designed for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have undergone prior systemic therapy, marking a significant advancement in treatment options.
- Patient Support Initiative: The newly launched 'Reimagine Recurrent LGSOC' campaign aims to provide emotional resonance and practical information for both patients and healthcare professionals, helping patients better manage their condition and set treatment expectations, thereby enhancing their quality of life.
- Market Demand Response: LGSOC is a rare cancer with a high recurrence rate, with approximately 30% of patients harboring KRAS mutations; Verastem's treatment not only fills a critical gap in this therapeutic area but also offers renewed hope for patients, potentially driving the company's growth in the biopharmaceutical market.
- Clinical Trial Plans: Verastem is conducting the international Phase 3 confirmatory trial RAMP 301 to evaluate the combination of AVMAPKI and FAKZYNJA against standard chemotherapy, further validating its clinical benefits to ensure continued FDA approval.
See More
RAMP 201 Clinical Trial Data Released
- Sustained Efficacy: In the RAMP 201 clinical trial, after a median follow-up of two years, 52% of patients with KRAS mutations and 30% of KRAS wild-type patients remained on therapy for over one year, indicating the durability and effectiveness of the treatment, potentially offering long-term options for patients.
- Good Safety Profile: The combination therapy demonstrated no new safety signals during the two-year follow-up, with only a 12% discontinuation rate due to adverse events, suggesting that the treatment regimen is well-tolerated over extended periods, thereby enhancing patient confidence in the therapy.
- Optimal Efficacy Analysis: Recent exposure-response analysis indicates that the best therapeutic effect of the combination therapy with avutometinib and defactinib is achieved at the approved doses, emphasizing the importance of dosing and scheduling, which provides guidance for clinical practice.
- Clinical Significance: The findings reveal that approximately one-third of patients without KRAS mutations continued treatment after one year, highlighting the importance of this combination therapy in a patient population with limited treatment options, potentially paving the way for new therapeutic strategies in the future.
See More
